Daxor

DXR

Market cap $62.6M

Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring'26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.

Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor's state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management.

OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater.

Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA).

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings.

Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 being held virtually on March 10 -11, 2026. Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET, and conduct virtual one-on-one meetings with institutional investors on March 11.

Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total net assets.

Expansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor's state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management.

OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions.